Abbott price target lowered to $115 from $132 at Oppenheimer

Oppenheimer lowered the firm’s price target on Abbott (ABT) to $115 from $132 and keeps an Outperform rating on the shares following quarterly results. The firm’s constructive outlook assumes subsiding non-MedTech headwinds, easier comps in FY26, and top-line composite growth ticking up to low-double digits, along with EBIT margins.